Key Takeaways
- Sales down 5% on price, not demand: Volumes grew 2% but price realization fell ~7%, compressing the top line even as underlying offtake held steady.
- Working capital swing drove cash negative: Operations consumed ₹900 cr as accounts payable dropped ₹750 cr on timely payments, pushing net working capital from ₹1,500 cr to ₹2,500 cr.
- Nutrition & Care is the standout: Both volumes (+8%) and prices (+4%) rose, a rare combination, lifting segment PBT from ₹20 cr to ₹30 cr for the half.
- China overcapacity is the persistent headwind: Pricing pressure in monomers, intermediates and now materials has no near-term relief in sight, with management calling a hockey-stick recovery unrealistic.
- What to watch next quarter: Whether receivables come down as promised, the pace of the Ag demerger regulatory process, and any stabilization in the monomers division after a one-third volume drop.
Top-Line & Profitability Drivers
- Volume-price split: 2% volume growth was more than offset by ~7% lower price realization, yielding a 5% sales decline. The half-year pattern is identical: volumes stable year-on-year, prices ~4% lower across the board.
- Sequential momentum: September quarter sales improved 4% over the June quarter, suggesting the trajectory is turning.
- PBT pressure: Higher raw material and input costs plus an unfavorable product mix compressed profitability beyond what the sales decline alone would explain.
- Opex ratio widened: Operating expenses moved from 11.5% to 13.2% of sales, driven by employee costs, severance, SAP systems upgrades across coatings and the core business, and FX hedging costs.
- Materials segment hit hardest: Down ₹400 cr, concentrated in the monomers division where volumes fell nearly one-third. Performance materials grew 4% but prices there fell 5%.
- Ag solutions weather-hit: A wet monsoon with untimely rain delayed and canceled spraying, reducing net offtake by ~₹80 cr. Soft commodity prices in intensive crops like chili, soybeans and cotton compounded the channel inventory overhang.
- Surface technologies (coatings): ₹280 cr in sales with both higher volumes and prices from key OEM customers. Half-year PBT was slightly lower due to one-time costs for setting up the new entity, but the recent three months were much better.
Gerding: "I think it would not be fair to say that we see an immediate sort of hockey stick type improvement. Yeah, I think we have to be realistic here."
Nutrition & Care: The Bright Spot
- Volume and price both up: 8% volume growth and 4% price increase, a combination no other segment achieved. The business contributed ₹1,700 cr to the half-year top line.
- PBT nearly doubled: Segment profit moved from ₹20 cr to ₹30 cr for the six months. Nutrition & health profits rose ~50% on both volume and price gains.
- Portfolio mix shift underway: Management is deliberately tilting toward higher-margin UV filters, personal care, skin care and hair care products, and away from the lower-margin audio chemical tolling business for Unilever.
- Care chemicals lagging: The manufacturing-heavy care chemicals sub-segment saw profits shrink to just ₹2 cr in six months, tempering the overall segment story.
- GST tailwind: The fast-moving consumer space, spanning personal care, skin care, hair care, and flavors & fragrances, is getting a lift from GST cuts.
Working Capital & Cash Flow
- Cash flow from operations: Negative ₹900 cr, driven entirely by net working capital movements.
- The payables effect: Accounts payable dropped ₹750 cr because payables were made on time, not because of any distress. This single item swung net working capital from ₹1,500 cr to ₹2,500 cr.
- Receivables improved: Down from ₹3,200 cr to ₹3,000 cr, a ₹200 cr reduction. Management expressed confidence that receivables will be brought down further by the December quarter.
- Inventory slightly up: A modest increase, with management equally confident inventory will be brought under control.
- Ag channel health: Despite the difficult season, BASF's own channel inventories and accounts receivable in ag solutions are in healthy shape heading into the rabi season.
China Overcapacity & Pricing Environment
- Upstream chemicals under pressure: Overcapacities built in China are clearly visible in the monomers and intermediates business, with pricing pressure now spreading into the materials segment.
- No near-term relief: Management sees the overcapacity combined with geopolitical tariffs as a difficult element likely to persist into 2026 unless something massive changes.
- Plastic additives specifically called out: Antioxidants and UV stabilizers face global overcapacity and a push from China; pricing pressure is expected to continue for a long time.
- India's asset utilization as a buffer: Management noted that Indian assets consistently run at 80-90% utilization, standing out against underutilized Western European assets, which provides some cost absorption.
Gerding: "India has always done exceptionally well to run, to sweat the assets. Yeah, and to do smart incremental investments once the asset utilization has gone to a very healthy level."
Strategic Actions & Restructuring
- Ag solutions demerger: A new company, BASF Agricultural Solutions India Limited, has been incorporated. The board approved a one-to-one share entitlement ratio; regulatory approvals with BSE and NSE are ongoing, with completion expected during FY 2627. The entity will be listed on stock exchanges.
- Coatings transaction with Carlyle: A binding agreement gives Carlyle 60% and BASF 40% equity stake globally. The global transaction is expected to close by Q2 calendar year 2026, subject to regulatory approvals. Evaluation of the effect on BASF India Coatings Private Limited is under process.
- Segment reclassification: The process catalyst business moved from Surface Technologies to Industrial Solutions, now clubbed under Performance Chemicals.
- Cost structure post-demerger: Management is carefully examining the cost base so that, once Ag is separated, the core chemicals business is not burdened with extra functional platform costs that Ag currently absorbs.
- Portfolio expansion intent: The company is constantly evaluating options, both organic and inorganic, to expand the product mix and strengthen core businesses post-demerger.
Gerding: "The expected demerger completion timeline will be during the financial year 2627 and BASF will eventually be also listed on the stock exchanges."
Capex & Capacity Build-Out
- Cellasto facility: A new facility is under construction, with commissioning targeted for the second half of 2026. The investment aims to increase own-manufactured product share in India and reduce imports from Germany.
- Cellasto asset upgradation at Dahej: Modernization will add capacity, automation, and efficiency. Once complete, parts currently imported from Germany can be localized, adding to the bottom line. Management declined to disclose the Capex amount or peak sales.
- Engineering plastics compounding: Extrusion line capacity at the Thane site expanded by 80%.
- Vessel reactivation at Thane: Enables more products in the system house.
- Green energy agreement: A 25-year hybrid solar and wind captive agreement with Clean Max will take energy consumption at Dahej and Panoli sites above 80%, with significant savings expected.
- Quality control lab: Upgraded and modernized at Thane, Navi Mumbai.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Receivables reduction | Bring receivables down further from current ₹3,000 cr | December quarter |
| Inventory control | Bring inventory under control | No specific date; confidence expressed |
| Ag solutions demerger completion | One-to-one share ratio; new entity listed | During FY 2627 |
| Coatings global transaction close | Carlyle 60%, BASF 40%; subject to regulatory approvals | Q2 calendar year 2026 |
| Cellasto new facility commissioning | New facility ready; capacity improvement and import substitution | Second half of 2026 |
| Green energy savings | Hybrid solar/wind captive agreement; Dahej and Panoli sites above 80% renewable | 25-year agreement signed |
| Cost structure post-demerger | Core chemicals not burdened with extra functional platform costs currently absorbed by Ag | By demerger completion |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹4,000 cr, down 5% YoY from ₹4,248 cr; volumes up 2%, prices down ~7% |
| Half-year revenue | ₹7,920 cr, down 4% YoY from ₹8,200 cr; volumes stable, prices down ~4% |
| PBT before exceptional items | 16% down YoY, 23% down QoQ; impacted by higher input costs and unfavorable product mix |
| Half-year PBT before exceptional items | 27% down YoY; PBT margin at 4.3% vs 5.6% last year |
| EPS before exceptional items | ₹56.5 (six months, not annualized) |
| Materials segment revenue | ~₹400 cr lower YoY (six months); monomers volumes down almost one-third |
| Nutrition & Care revenue | ₹1,700 cr (six months); volumes up ~8%, prices up 4% |
| Nutrition & Care PBT | ₹30 cr (six months), up 50% YoY from ₹20 cr; nutrition and health profits nearly doubled from ₹14 cr to ₹27 cr |
| Agriculture Solutions revenue | ~₹80 cr lower YoY (six months); impacted by wet monsoon, delayed and canceled spraying |
| Surface Technologies (Coatings) revenue | ₹280 cr (six months); higher volumes and price from key OEM customers |
| Industrial Solutions revenue | ₹1,400 cr (six months), stable; EBIT margin currently 5% |
| Net working capital | ₹2,500 cr vs ₹1,500 cr YoY; receivables down to ₹3,000 cr, accounts payable down ₹750 cr to ₹3,350 cr |
| Cash flow from operations | -₹900 cr (six months); driven by lower accounts payable and higher receivables |
| Operating expenses (ex-COGS) | 13.2% of sales vs 11.5% YoY; higher employee costs, severance, SAP upgrade, and FX hedging costs |
| RoSI | 9.4% (six months, not annualized) |
| Return on net operating assets | 10.6% (six months, not annualized) |
| Receivable days | 65 days; 10–12% of receivables still under control |